Today I closed out one of the most controversial positions in the Fat Pitch Financials Portfolio, Merck (MRK). The 5,000 shares of Merck held in the Fat Pitch Financials Portfolio at Marketocracy were sold today for $56.00. I just got an email indicating that the 5,000 shares were sold at a net average price of $55.956 including commissions and fees. I
I was just reviewing the new stories queue at Value Investing News when I discovered that Warren Buffett’s Berkshire Hathaway was named ‘Most Respected’ by a Barron’s survey. This doesn’t come as any real surprise to me. It’s really about time that Buffett’s company was recognized as a true corporate leader. Some have speculated that
I’m a little behind on updating you on the performance of the Fat Pitch Financials Portfolio. Let me quickly update you on how my virtual portfolio did in May. Last month, the Fat Pitch Financials Port returned 1.48%. The S&P 500 returned 3.22% over the same period, so I trailed the index by 1.73%. I’ve
Pfizer (PFE) is a world class pharmaceutical company that develops and manufactures leading prescription medicines. This $181 billion dollar company has many competitive advantages that give it a wide moat, which shields it from the pressures of profit eroding competition.
Here is my Marketocracy buy order confirmation for yesterday’s purchase of Pfizer stock: Your ticket to buy 2010 shares of PFE at $24.8500, created at 09:52 Dec 07 completed at 10:04 Dec 07. 2010 shares were bought at a net average price of $24.9000 including commissions and fees. You can track the performance of this
This is just a quick note to let you know that Pfizer Inc. (PFE) has been added to the FPF Port. I encourage you to run my Fat Pitch Finder Spreadsheet to see some of the rationale behind my purchase of this wide moat stock. I will follow up shortly with more details regarding this